CIK 0001001233
- Non-accelerated filer
- Smaller reporting company
SANGAMO THERAPEUTICS, INC
Sign in to watch- Ticker
- SGMOQ
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680359556
- Phone
- +1 510-970-6000
- Business address
- 501 CANAL BLVD., RICHMOND, CA, 94084
- Former names
- SANGAMO BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-24 | Dubois-Stringfellow Nathalie SVP-Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +249,375 | 249,375 | ||
| 2023-02-24 | Fontenot Jason D. SVP, Chief Scientific Officer | Grant or award | +42,750 | 145,917 | ||
| 2023-02-24 | Fontenot Jason D. SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +199,500 | 199,500 | ||
| 2023-02-24 | Duraibabu Prathyusha SVP, Chief Financial Officer | Grant or award | +53,438 | 140,755 | ||
| 2023-02-24 | Duraibabu Prathyusha SVP, Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +249,375 | 249,375 | ||
| 2023-02-24 | Macrae Sandy President, CEO and Director | Grant or award | +157,300 | 678,476 | ||
| 2023-02-24 | Macrae Sandy President, CEO and Director | Grant or award · Stock Option (Right to Buy) | +734,050 | 734,050 | ||
| 2022-12-15 | Horn Margaret A Director | Grant or award | +18,750 | 18,750 | ||
| 2022-12-15 | Horn Margaret A Director | Grant or award · Stock Option (Right to Buy) | +37,500 | 37,500 | ||
| 2022-12-15 | Beers Courtney Director | Grant or award | +18,750 | 18,750 | ||
| 2022-12-15 | Beers Courtney Director | Grant or award · Stock Option (Right to Buy) | +37,500 | 37,500 | ||
| 2022-08-30 | BIOGEN INC. 10% owner | Sale | −100,000 | $5.27 | $527K | 23,652,466 |
| 2022-08-29 | BIOGEN INC. 10% owner | Sale | −400,000 | $5.33 | $2.1M | 23,752,466 |
| 2022-08-13 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Shares withheld for taxes | −864 | $6.33 | $5K | 92,966 |
| 2022-06-25 | McClung David Mark EVP, Chief Operating Officer | Shares withheld for taxes | −11,525 | $4.31 | $50K | 175,816 |
| 2022-06-11 | Duraibabu Prathyusha SVP, Chief Financial Officer | Shares withheld for taxes | −864 | $3.76 | $3K | 86,595 |
| 2022-06-11 | Duraibabu Prathyusha Vice President, Finance | Shares withheld for taxes | −842 | $3.76 | $3K | 86,617 |
| 2022-06-03 | Markels John Director | Purchase | +6,784 | $3.69 | $25K | 32,484 |
| 2022-06-01 | PARKER H STEWART Director | Purchase | +5,000 | $3.60 | $18K | 48,700 |
| 2022-04-29 | Willoughby Scott B. SVP, Gen. Counsel & Secretary | Shares withheld for taxes | −140 | $4.15 | $581 | 90,709 |
Page 12 of 17 · 338 trades